Burlington Coat Factory Raises $3 million for the LLS

For the 12th straight year, Burlington Coat Factory has raised a significant amount of money to benefit the Leukemia and Lymphoma Society (LLS).

One of the perennial big fundraisers for the LLS, this past year Burlington carried out its annual fundraiser over a 17-week campaign that ran from July through October. The company joined LLS in its Light The Night campaign to raise funds to help find cures and ensure access to treatments for patients with blood cancer by encouraging customers to make a donation at checkout.

The 2013 campaign raised more than $3 million, bringing the total raised by the company over the many years of its partnership with the LLS to more than $19 million.

Burlington has a long history of partnering with LLS

"A strong commitment to community has long been a part of our heritage," said Tom Kingsbury, president and CEO of Burlington. "Our long-standing partnership with LLS and its Light The Night campaign continues to allow us to help those affected by cancer in a meaningful way by engaging our associates and customers. We look forward to growing this important partnership in 2014 and to supporting LLS to achieve [its] ultimate goal of a world without blood cancers."

Burlington not only encourages customers to make a donation at checkout, but its 28,000 employees also take part in Light The Night walks all over the United States as a means of helping to raise money for LLS.

"As our #1 National Corporate Partner for Light The Night, Burlington is playing a role in helping us to change the cancer landscape," said John Walter, LLS president and CEO. "Burlington and the Light The Night campaign have helped LLS invest almost $1 billion in our mission to cure blood cancers and ensure access to treatments."

Source: LLS

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap